Literature DB >> 23750936

Spinal muscular atrophy: new findings for an old pathology.

Daniele Bottai1, Raffaella Adami.   

Abstract

Understanding the events that are responsible for a disease is mandatory for setting up a therapeutic strategy. Although spinal muscular atrophy (SMA) is considered a rare neurodegenerative pathology, its impact in our society is really devastating as it strikes young people from birth onward, and it affects their families either emotionally or financially. Moreover, it requires intensive care for the children, and this diverts both parents and relatives from their occupations. Each neuron is very different from one another; therefore, in a neurodegenerative disease, the population of axons, synapses and cell bodies degenerate asynchronously, and subpopulations of neurons have different vulnerabilities. The knowledge of the sequence of events along the lengths of individual neurons is crucial to understand if each synapse degenerates before the corresponding axon, or if each axon degenerates before the corresponding cell body. Early degeneration of one neuronal compartment in disease often reflects molecular defects somewhere else. Up until now, SMA is considered mostly a lower motor neuron disease caused by the loss-of-function mutations in the SMN1 gene; here, we inspect other features that can be altered by this defect, such as the cross talk between muscle and motor neuron and the role of physical inactivity.
© 2013 International Society of Neuropathology.

Entities:  

Keywords:  NMJ; SMN1; SMN2; cardiotrophin 1; miRNA; muscle activity; spinal muscular atrophy

Mesh:

Substances:

Year:  2013        PMID: 23750936     DOI: 10.1111/bpa.12071

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  9 in total

Review 1.  Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?

Authors:  Monir Shababi; Christian L Lorson; Sabine S Rudnik-Schöneborn
Journal:  J Anat       Date:  2013-07-22       Impact factor: 2.610

Review 2.  Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Stem Cell Rev Rep       Date:  2019-12       Impact factor: 5.739

3.  Ultrastructural characterization of peripheral denervation in a mouse model of Type III spinal muscular atrophy.

Authors:  Federica Fulceri; Francesca Biagioni; Fiona Limanaqi; Carla L Busceti; Larisa Ryskalin; Paola Lenzi; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2021-05-17       Impact factor: 3.575

Review 4.  Stem cell transplantation in neurological diseases: improving effectiveness in animal models.

Authors:  Raffaella Adami; Giuseppe Scesa; Daniele Bottai
Journal:  Front Cell Dev Biol       Date:  2014-05-14

Review 5.  Neuromuscular Junctions as Key Contributors and Therapeutic Targets in Spinal Muscular Atrophy.

Authors:  Marina Boido; Alessandro Vercelli
Journal:  Front Neuroanat       Date:  2016-02-03       Impact factor: 3.856

6.  Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III.

Authors:  Heike Kölbel; Berthold P Hauffa; Stefan A Wudy; Anastasios Bouikidis; Adela Della Marina; Ulrike Schara
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

7.  Reduction of Movement in Neurological Diseases: Effects on Neural Stem Cells Characteristics.

Authors:  Raffaella Adami; Jessica Pagano; Michela Colombo; Natalia Platonova; Deborah Recchia; Raffaella Chiaramonte; Roberto Bottinelli; Monica Canepari; Daniele Bottai
Journal:  Front Neurosci       Date:  2018-05-23       Impact factor: 4.677

Review 8.  Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment.

Authors:  Giovanna Menduti; Daniela Maria Rasà; Serena Stanga; Marina Boido
Journal:  Front Pharmacol       Date:  2020-11-12       Impact factor: 5.810

Review 9.  S-adenosylmethionine tRNA modification: unexpected/unsuspected implications of former/new players.

Authors:  Raffaella Adami; Daniele Bottai
Journal:  Int J Biol Sci       Date:  2020-09-30       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.